Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR.
about
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughDigoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung CancerHigh expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patientsTransforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cellsNeoadjuvant treatment for resectable pancreatic adenocarcinoma.Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive propertiesActivation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC.Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.Paradoxical roles of dual oxidases in cancer biology.A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy.MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling.Circulating tumor cells in lung cancer: cluster circulating tumor cells as hybrid epithelial-mesenchymal transition/mesenchymal-epithelial transition (E/M).The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis
P2860
Q26749110-B08210D8-6553-4172-96C1-4BFCA0E2C062Q26799467-B8BC4380-F5CB-4CD3-9C9D-405DAC5D3AD3Q35587056-F127364B-2892-46E0-9A6B-E503F672C08EQ35632310-3B5C9369-F496-4F74-ADB9-74D8CEF437D6Q35827597-87C60BE8-7C54-446A-BA59-77E0F8ED0626Q36526141-4850C4C7-F3B6-4794-A15D-D136DA8BACE5Q36688968-220DF3DF-C1E4-4FA5-ACE2-EF5FAB4FCAB6Q37426768-1997E86A-9FE9-4A95-BBCB-B6FA8C316FF4Q38603815-75FA71E3-CA57-4934-BDCF-6E2BD346450BQ38711211-C7D1A325-53FA-4C59-8EEE-D9213A651231Q39179464-EB85FCEC-EF5A-43A0-8F0C-2D22B3BC5E10Q39348472-0F11325C-72C9-4185-91C7-140DDCFE34B5Q41027999-B991DB3B-4D4F-4E77-B948-F99849A290D5Q41214544-1D7AAA04-84E1-4DDE-808C-8827F109D854Q41709272-8F2097C2-8C57-4D03-9069-95BCA431F29EQ42371545-05FCF9B2-E6EC-4E0D-962B-2B74BCD46392Q47135792-2E1C8437-F7B1-4E3A-9416-89DE71CC8877Q49963088-7C7520BB-9434-4A93-B41C-B9351915181BQ50053003-CC703450-2172-4D53-AD7A-D994648B0AC0Q54115504-52AEABA3-2B89-4053-A760-07A0B1AA8672Q58803156-702C3352-B4B8-4FD4-B885-92BAE81D0DD0
P2860
Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Epithelial phenotype as a pred ...... patients with wild-type EGFR.
@en
Epithelial phenotype as a pred ...... patients with wild-type EGFR.
@nl
type
label
Epithelial phenotype as a pred ...... patients with wild-type EGFR.
@en
Epithelial phenotype as a pred ...... patients with wild-type EGFR.
@nl
prefLabel
Epithelial phenotype as a pred ...... patients with wild-type EGFR.
@en
Epithelial phenotype as a pred ...... patients with wild-type EGFR.
@nl
P2093
P2860
P356
P1476
Epithelial phenotype as a pred ...... patients with wild-type EGFR.
@en
P2093
Caicun Zhou
Chunyan Wu
Gerald Schmid-Bindert
Guanghui Gao
Guotong Xu
Jiawei Ren
P2860
P304
P356
10.1002/IJC.28925
P50
P577
2014-05-07T00:00:00Z